INSTITUTIONAL REVIEW BOARD APPLICATION
Review the IRB website for information about what type of IRB review applies to your study
(https://research.kennesaw.edu/irb/review-classifications.php)
Review type:
___Check here for a Request for Exemption
__X_Check here for an Expedited Review [IRB Reviewers may recommend a Full Board Review]
Status of Primary Investigator:
_X__Faculty

___Staff

___Student

Students as the Primary Investigator (PI) and their Faculty Advisors
Students (graduate and undergraduate) must have a faculty advisor complete the last page of
this form and submit all documents from the faculty advisor’s KSU email address. Students
must also use their KSU email address in all IRB correspondence.
By submitting this form, you agree that you have read KSU’s Federal-wide Assurance of
Compliance and agree to provide for the protection of the rights and welfare of your research
participants as outlined in the Assurance. You also agree to submit any significant changes in
the procedures of your project to the IRB for prior approval and agree to report to the IRB any
unanticipated problems or adverse events involving risks to subjects or others.

Title of Research
The Phoenix Sign: Is it due to vasodilation? Blinded prospective comparing the
effects of papaverine to lidocaine without epinephrine

Start Date is date of IRB approval

Proposed start date: ____3/1/2020__________

*The official start date for research is the date the IRB approval letter is issued. Research
activities may not begin prior to final IRB approval. Studies should be submitted well in advance
of the proposed start date to allow for processing, review, and approval. If you have not received
a letter from the IRB in 10 business days of submission, please call or email requesting status
update.

Is your research being funded in any way? ___Yes* __X_ No
*Where is the funding coming from? [Name of Federal Agency/Foundation/Department]
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If you have obtained funding, please submit your award documentation along with this
application.

Primary Investigator
All IRB correspondence goes only to the primary investigator (PI) and advisors are
copied on student projects.
Name:
Stephen L. Barrett, D.P.M., FACFAS FAENS
Department:
Molecular and Cellular Biology
Telephone:

Email: sbarre52@kennesaw.edu

832-524-7254
FOR RESEARCH CONDUCTED BY STUDENTS AS THE PRIMARY INVESTIGATOR, GO
TO THE LAST PAGE OF THE APPLICATION FORM TO ENTER REQUIRED FACULTY
ADVISOR INFORMATION.

Co-Investigator(s) who are faculty, staff, or students at KSU
Name: Kerry McCardel
Email: kmccard1@students.kennesaw.edu
Name: Destiny Page
Email: dpaige2@students.kennesaw.edu
Name: Cynney Walters
Email: cwalte43@students.kennesaw.edu

____Faculty
____Staff
__X__Student
____Faculty
____Staff
__X__Student
____Faculty
____Staff
__X__Student

Additional Names (include status and email):
Adam Kahn Student akhan42@students.kennesaw.edu

Co-Investigator(s) who are NOT employees or students at KSU: Please
submit your human participants training certificate with application
materials.
Name: Sequioa DuCasse, D.P.M., MS
Email: sducasse.dpm@gmail.com
Home Institution: US Neuropathy Centers, LLC
Name: Porscha Bailey, D.P.M.
Email: porschaba@gmail.com
Home Institution: US Neuropathy Centers, LLC
Additional Names (include email and home institution):
Nia Mitchell US Neuropathy Centers LLC nia.m.mitchell@gmail.com
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ALL researchers listed on this application MUST have completed CITI training BEFORE
an IRB Approval will be provided.
Visit http://research.kennesaw.edu/irb/citi-training.php for additional information about CITI
training, how to choose the right course, and how to create a profile. ALL KSU
faculty/staff/students MUST use their KSU provided email address on all correspondence.
NOTE: It is each researcher’s responsibility to ensure that the CITI Certificate does not
expire during the course of the approved study. Failure to maintain a current certificate
will invalidate your approval. Please use your KSU email address on your CITI profile
and make sure your profile name matches the one provided above.

Does your research involve minors? ___Yes
__X_No
See item number 5 below for parental consent and minor assent information. See
http://research.kennesaw.edu/irb/consent-templates.php for forms and information.
Will this research involve COLLABORATION with ANOTHER INSTITUTION?
___Yes

__X_No, go to question 1

If yes, provide the name of the Institution __________________________________
Has the other Institution conducted an IRB review of the study?
___No

___Yes – Send that review with this approval form to the KSU IRB.

1. Prior Research
Have you submitted research on this topic to the KSU IRB previously? _X__Yes* ___ No
*If yes, list the date, title, name of investigator, and study number:

Study 20-143: Sonographically Guided Infiltration of Low dose
infiltration of 1% lidocaine as a Predictor for the Efficacy of
Surgical Peripheral Nerve Decompression 11/6/2019 PI: Stephen L.
Barrett, D.P.M.
See http://research.kennesaw.edu/irb/application-tips.php for detailed explanations of
questions 2-8. Provide complete sentences with sufficient information for an IRB review.
2. Description of Research
a. Purpose of and anticipated findings for this study:
A neurological phenomenon has been observed clinically that when after a
small amount of 1% lidocaine (usually less than .5cc’s) has been infiltrated
adjacent to the Common Fibular (Peroneal) nerve under sonographic
guidance, in patients with drop foot, or significantly weakened motor
potentials of the lower extremity dorsiflexors (Extensor Hallucis Longus
(EHL), Tibialis Anterior (TA), and Extensor Digitorum Longus (EDL)), the
patient will regain partial or full dorsiflexion temporarily during the effect of
this nerve block. This has been named the Phoenix Sign, in reference to
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ancient Greek folklore, as the non-functioning nerve (like the bird) becomes
functional due to the effect of lidocaine, similar in a way that the mythical bird
rose from the ashes. This sign has significant benefit to the diagnosis and
assessment of Common Fibular (Peroneal) nerve palsy as clinically when a
nerve does not manifest a Tinel’s or Provocation sign it is believed that the
nerve damage is so severe that peripheral nerve decompression will not
likely benefit the patient. However, when a patient manifests a “positive
Phoenix sign” the prognosis has been greater than 90%--that the patient will
gain improvement in motor function of the dorsiflexors of the lower extremity
after surgical decompression. Thus, many patients with this crippling
condition are not receiving definitive treatment because of the inability of
standard clinical work-up and diagnosis. A “positive Phoenix sign” also
differentiates a focal nerve compression peripherally versus a central CNS
manifestation. It is hypothesized that this observation of improved nerve
function is due to the vasodilatory nature of the local anesthetic. By
comparing the block given with lidocaine versus papaverine (a known
vasodilator), the vasodilation hypothesis can be tested. The purpose of this
study is to help determine if this is a valid explanation for the phenomenon.
b. Nature of data to be collected (interview (includes focus groups), online or hardcopy
survey, observations, experimental procedures, etc.):
This study is doubly blinded so that the clinician and the patient do not know
what infiltrate is being used. They will be consented to have either an
infiltration of lidocaine, or papaverine. All of these compounds are FDA
approved for human use, and all are commonly used in clinical practice. If
the “Phoenix Sign” is observed in the both the lidocaine and papaverine arms
it would provide compelling evidence that this phenomenon is due to the
vasodilation effect of the local anesthetic. A comparison could lend credence
to solely using papaverine clinically.
Data that will be collected:
1. Pre-infiltration EHL, TA and EHL strength assessment as measured
clinically on a 1-5/5 scale and with a dynamometer.
2. Pre-infiltration pain assessment as measured on a 1-10 VAS pain
scale
3. Post-infiltration at 4 minutes after injection EHL, TA and EHL strength
assessment as measured clinically on a 1-5/5 scale and with a
dynamometer
4. Post-infiltration pain assessment as measured on a 1-10 VAS pain
scale
5. Length of duration of the effect-if any

c. Data collection procedures: (include information on how consent will be obtained, how
links will be provided, where interviews will be conducted, audio or video taping, etc.).
Note: student email addresses are FERPA protected. Student email addresses,
grades, or work cannot be collected without student consent and IRB approval.
Informed Consent will be obtained in the clinical setting from patients
KSU IRB Approval Form – updated 10.2.19 (replaces all previous versions and must be used)
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d. Survey instruments to be used (pre-/post-tests, interview and focus group
questionnaires, online surveys, standardized assessments etc.). Attach all survey
instruments with your application document):

e. Method of selection/recruitment of participants:
Refer to the KSU Mass Email policy on the use emails to faculty/staff. For student
recruitment via email, please also follow these mandatory instructions. ALL
recruitment materials (flyers, emails, posters, etc.) MUST include your IRB Approval
Study # and a statement that your study has been reviewed and approved by KSU’s
IRB.
Subjects will be recruited from our existing clinical practice.
f. Participant age range: __18-85__ Number: _20___
Sex: __Males __ Females or

20__Both

g. Incentives, follow-ups, compensation to be used: (e.g., Gift cards, course credit, etc.).
Please visit HERE on our website for guidelines on participant incentive payments.
No incentives will be given to the subjects
3. Risks
Describe in detail any psychological, social, legal, economic, or physical risk that might occur
to participants. Note that all research may entail some level of risk, though perhaps minimal.
According to the federal regulations at §46.102(i), minimal risk means that the probability and
magnitude of harm or discomfort anticipated in the research are not greater in and of
themselves than those ordinarily encountered in daily life or during the performance of routine
physical or psychological examinations or tests.
_X_ There is minimal risk (if selected, must be reflected within consent documents)
__ There is more than minimal risk (requires full explanation below and in consent documents)
Anticipated risks include (if selected, specific potential risks must be incorporated into
the consent documents):

If more than minimal risk is anticipated, describe your method for handling risk.

4. Benefits
Federal Guidelines and University policy require that risks from participation be outweighed by
potential benefits to participants and/or humankind in general.
KSU IRB Approval Form – updated 10.2.19 (replaces all previous versions and must be used)
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a. Identify potential benefits to participants resulting from this research (It is possible that
there are no direct benefits or possible specific benefits, either must be reflected in the
consent documents):
As a positive “phoenix sign” is highly predictive of a positive result after surgical
peripheral nerve decompression surgery the subject will have the benefit of an
additional level of diagnosis and assessment of their particular level of nerve
status or function.
b. Identify benefits to humankind in general resulting from this research. While there may
be no potential benefits to participants there must be some benefit to humankind in
order to receive IRB approval. Please include these benefits in the consent documents:
There are many patients who suffer from drop foot due to an entrapment of the
Common Fibular (Peroneal) nerve who are told that there is nothing that can be
done for them to restore their function, and that only bracing with an ankle foot
orthosis can be done. Drop foot is a crippling condition, that in many cases can
be completely reversed, that subjects the patient to not only a decreased quality
of life, but increased falls—which have a very high level of mortality in the aging
population. Validation of the hypothesis could lead to wider clinical
implementation affording patients additional diagnostic data.

5. Informed Consent
All studies of human participants must include informed consent (see IRB approved
templates). Consent may require a signature or may simply require that participants be
informed. Minor participants must receive an assent form in conjunction with parental consent
(see IRB approved templates). If deception is necessary, please justify and describe, and
submit debriefing procedures.
What is the consent process to be followed in this study? Submit your consent form(s) with the
application as a separate document(s).
See attached consents
6. Online Surveys (For all electronic surveys, you must submit a link to the final version
of the survey.)
Will you use an online survey to obtain data from human participants in this study?
Check all that apply.
_X_ No. If no, skip to Question 7 below.
__Yes, I will use an online survey to obtain data in this study. If yes:
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a. How will online data be collected and handled? Select one and add the chosen
statement to your consent document.
__ Data collected online will be handled in an anonymous manner and Internet
Protocol addresses WILL NOT be collected by the survey program.
__ Data collected online will be handled in a confidential manner (identifiers will be
used), but Internet Protocol addresses WILL NOT be collected by the survey
program.
__ Data collected online will be handled in a confidential manner and Internet
Protocol addresses WILL be collected by the survey program.
b. Include an “I agree to participate” and an “I do not agree to participate” answer at the
bottom of your consent document. Program the “I do not agree to participate” statement
to exclude the participant from answering the remainder of the survey questions (this is
accomplished through "question logic" in Survey Monkey or “skip logic” in Qualtrics).
Ensure that the online consent document is the first page the participant sees after clicking on
the link to your online survey.
Although you may construct your own consent document, see the IRB approved Online Survey
Cover Letter template (http://research.kennesaw.edu/irb/consent-templates.php), which
contains all of the required elements of informed consent that must be addressed within any
online consent document.
7. Vulnerable Participants
Will minors or other vulnerable participants (e.g., prisoners, pregnant women, those with
intellectual disabilities) be included in this research?
__Yes. Outline procedures to be used in obtaining the agreement (parental consent, assent or
guardian consent) for vulnerable participants. Describe plans for obtaining consent of the
parent, guardian, or authorized representative of these participants. For research conducted
within the researcher’s own classroom, describe plans for having someone other than the
researcher obtain consent/assent so as to reduce the perception of coercion.

_X_ No. All studies excluding minors as participants should include language within the
consent document stating that only participants aged 18 and over may participate in the study.
8. Future Risks
How are participants protected from the potentially harmful future use of the data collected in
this research?
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a. Describe measures planned to ensure anonymity or confidentiality. Studies can only be
considered completely anonymous if no identifying information is collected; therefore, a
cover letter must be used in place of a signed consent form.
At the time a person becomes a patient in our practice, they are offered the
opportunity to be part of clinical research. They also have the option to not
participate. The form is attached that they are given at the time of them
becoming a new patient. If they give this general consent, they allow us to
report data without anonymity, but will have additional informed consent for
this study. That consent is attached with this application
b. Describe methods for storing data while study is underway. Personal laptops are not
considered secure.
Data will be kept in our encrypted electronic medical record keeping system, and
patient data will only be referenced to by non-identifying initials, age, and sex in
any reporting of the data.

c. List dates and plans for storing and/or destroying data and media once study is
completed. Please note that all final records relating to conducted research, including
signed consent documents, must be retained for at least three years following
completion of the research and must be accessible for inspection by authorized
representatives as needed.
Data will be stored for a minimum of 7 years or as directed by any authoritative
body participating in the research.

d. If digital audio, video, or other electronic data are to be used, when will they be
destroyed?
See above

9. Illegal Activities
Will collected data relate to any illegal activities? __Yes* _X_No
This includes asking about illegal activities from participants or surveys containing any
reference to illegal activities (e.g., questions requesting information about witnessing illegal
behaviors that others have engaged in, minors drinking or using drugs, or any illegal drug use
or violence of any nature that would result in legal action).
*If yes, please explain.
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Is My Study Ready for Review?
Every research protocol, consent document, and survey instrument approved by the IRB is
designated as an official institutional document; therefore, study documents must be as
complete as possible. Research proposals containing spelling or grammatical errors, missing
required elements of informed consent (within consent or assent documents), not addressing
all questions within this form, or missing required documents will be classified as incomplete.
All studies classified as incomplete may be administratively rejected and returned to the
researcher and/or faculty advisor without further processing.
If you are a non-KSU researcher wishing to recruit participants from the KSU campus, please
follow these instructions: https://research.kennesaw.edu/irb/international-research.php
Student researchers make sure that your faculty advisor completes the following page
and sends all study related material from their KSU email address to
irb@kennesaw.edu. Failure to follow this procedure will result in a significant delay in
the approval process.

RESEARCH CONDUCTED BY UNDERGRADUATE AND GRADUATE
STUDENTS AS PRIMARY INVESTIGATORS
All undergraduate and graduate students who will be acting as the Primary Investigator must
be under the direct supervision of a faculty advisor. The faculty advisor must review the IRB
application materials and agrees to supervise the student’s proposed human subject research
project by completion and submission of this routing sheet.
All application materials must be submitted by the faculty advisor from their KSU email address
to irb@kennesaw.edu. Students may not submit their materials to the IRB for the first review;
however, subsequent revisions can be sent directly to irb@kennesaw.edu with a cc to your
advisor and MUST come from your KSU provided email account.
FOR RESEARCH CONDUCTED BY STUDENTS OR NON-FACULTY STAFF. This study, if
approved, will be under the direct supervision of the following faculty advisor who is a member
of the KSU faculty:
Faculty Advisor
Name:
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Department:
Email:

Phone:

By checking the items below and submitting all materials from your KSU email, the faculty
advisor for this project attests the following:
___I have personally reviewed each of my student’s IRB application documents (approval
request, exemption request, informed consent documents, child assent documents, survey
instruments, etc.) for completeness, and all documents pertaining to the conduct of this study
are enclosed (consents, assents, questionnaires, surveys, assessments, etc.)
___ I have completed the Social/Behavioral Research course (Biomedical version only for
medical/biological human studies) CITI training course in the ethics of human subject research
within the past three years as have all researchers named within this application.
___I approve this research and agree to supervise the student(s) as the study is conducted.

Date: _________
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